Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07161544 · ClinicalTrials.gov registry record · Phase 1
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
A Phase 1 study of Stargardt Disease, sponsored by AAVantgarde Bio Srl.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 6
- Study locations
NCT07161544 is a Phase 1 study of Stargardt Disease that is actively recruiting participants, run by AAVantgarde Bio Srl. The registered enrollment target is 75 participants, below the 87-participant average among 16 other Stargardt Disease trials with a reported enrollment target (14% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT07161544, a Phase 1 study of Stargardt Disease, is actively recruiting participants, sponsored by AAVantgarde Bio Srl.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
Conditions Studied
Interventions
- BIOLOGICAL AAVB-039
Study Locations (6)
Texas
- Retina Consultants of Texas - Bellaire
- Retina Foundation of the Southwest - Dallas
England
- Moorfields Eye Hospital NHS Foundation Trust - London
- The Retina Clinic - London
California
- Retina Vitreous Associates Medical Group - Los Angeles
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2032-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07161544
The ClinicalTrials.gov registry entry for NCT07161544 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 16 other Stargardt Disease trials with a reported enrollment target (14% lower). The listed sponsor is AAVantgarde Bio Srl, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stargardt Disease appearing as the primary indexed condition, and to 1 intervention - of which AAVB-039 is the first listed.
NCT07161544 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, England, California.
Frequently Asked Questions
What is clinical trial NCT07161544 about?
NCT07161544 is a clinical study titled "A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)". The purpose of the 039-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-039 in participants with Stargardt disease secondary to a biallelic mutation of the ABCA4 gene. The study will also assess initial efficacy following AAVB-039 administration.
What is the current status of trial NCT07161544?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-09-29. Estimated completion is 2032-07.
What conditions does trial NCT07161544 study?
This clinical trial studies the following conditions: Stargardt Disease.
What interventions are being tested in trial NCT07161544?
The interventions under investigation include: AAVB-039 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07161544?
This trial is sponsored by AAVantgarde Bio Srl, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07161544 being conducted?
This trial has 6 study locations across California, Minnesota, Texas, England. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
RECRUITING · Phase 1
-
Oral Metformin for Treatment of ABCA4 Retinopathy
RECRUITING · Phase 1
-
Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
RECRUITING · Phase 1
-
An Observational Study in Children and Adults With Stargardt Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.